Immunosyn Execs Hit With $20M Insider Trading Suit
Executives at San Diego biotechnology firm Immunosyn Corp. hyped an experimental HIV drug, raising $20 million from investors, then sold their shares without disclosing that the drug's approval process was on...To view the full article, register now.
Already a subscriber? Click here to view full article